Indicated in adults for the prevention of nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month of age.
Ozenoxacin is indicated for the topical treatment of impetigo in patients aged 2 months and older.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ozanex and other antibacterial drugs, Ozanex should be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Registration
Biological Drug
FluMist
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage)
SFDA Approved Use
FluMist is indicated for the prophylaxis of influenza in individuals from 2 to less than 18 years of age.
Loncastuximab Tesirine as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
For sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e., procedural/awake sedation.
• Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
• Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
• Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Marstacimab is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:
·severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
·severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.
